Christopher K Payne

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi Research criteria versus clinical criteria for interstitial cystitis
    Christopher K Payne
    Department of Urology, Stanford University, Stanford, CA, USA
    Int J Urol 10:S7-S10. 2003
  2. ncbi Goal achievement provides new insights into interstitial cystitis/painful bladder syndrome symptoms and outcomes
    Christopher Payne
    Female Neurourology, Stanford School of Medicine, Stanford, CA 94305 5118, USA
    Neurourol Urodyn 28:13-7. 2009
  3. ncbi Redefining response in overactive bladder syndrome
    Christopher K Payne
    Department of Urology, Stanford University Medical School, Stanford, CA 94305, USA
    BJU Int 99:101-6. 2007
  4. ncbi Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial
    Christopher K Payne
    Stanford University School of Medicine, Stanford, California, USA
    J Urol 173:1590-4. 2005
  5. ncbi Pilot study of the feasibility of in-office bladder distention using electromotive drug adminstration (EMDA)
    Amy E Rose
    Department of Urology, Stanford University Medical School, Stanford, California 94305, USA
    Neurourol Urodyn 24:254-60. 2005
  6. ncbi Sacral neuromodulation in patients with interstitial cystitis: a multicenter clinical trial
    Kristene E Whitmore
    Department of Urology, Graduate Hospital, Philadelphia, Pennsylvania, USA
    Int Urogynecol J Pelvic Floor Dysfunct 14:305-8; discussion 308-9. 2003
  7. ncbi Office bladder distention with electromotive drug administration (EMDA) is equivalent to distention under general anesthesia (GA)
    Amy E Rose
    Department of Urology, Stanford University Medical School, Stanford, California, USA
    BMC Urol 5:14. 2005
  8. ncbi Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome
    Jennifer T Anger
    Department of Urology, UCLA, Box 951738, Los Angeles, CA 90095 1738, USA
    Int Urogynecol J 22:395-400. 2011
  9. ncbi Solifenacin in overactive bladder syndrome
    Christopher K Payne
    Section of Female Urology and NeuroUrology, Stanford University School of Medicine, Stanford, California 94305-5118, USA
    Drugs 66:175-90. 2006
  10. ncbi Correlation between 2 interstitial cystitis symptom instruments
    Erenee Sirinian
    Stanford University Medical Center, Stanford, California, USA
    J Urol 173:835-40. 2005

Research Grants

  1. Interstitial Cystitis Clinical Research Network
    Christopher Payne; Fiscal Year: 2007

Detail Information

Publications17

  1. ncbi Research criteria versus clinical criteria for interstitial cystitis
    Christopher K Payne
    Department of Urology, Stanford University, Stanford, CA, USA
    Int J Urol 10:S7-S10. 2003
    ....
  2. ncbi Goal achievement provides new insights into interstitial cystitis/painful bladder syndrome symptoms and outcomes
    Christopher Payne
    Female Neurourology, Stanford School of Medicine, Stanford, CA 94305 5118, USA
    Neurourol Urodyn 28:13-7. 2009
    ..We used surveys and focus groups to characterize the goals of patients with interstitial cystitis/painful bladder syndrome (IC/PBS) in order to create a pilot GAS...
  3. ncbi Redefining response in overactive bladder syndrome
    Christopher K Payne
    Department of Urology, Stanford University Medical School, Stanford, CA 94305, USA
    BJU Int 99:101-6. 2007
    ....
  4. ncbi Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial
    Christopher K Payne
    Stanford University School of Medicine, Stanford, California, USA
    J Urol 173:1590-4. 2005
    ....
  5. ncbi Pilot study of the feasibility of in-office bladder distention using electromotive drug adminstration (EMDA)
    Amy E Rose
    Department of Urology, Stanford University Medical School, Stanford, California 94305, USA
    Neurourol Urodyn 24:254-60. 2005
    ..Lidocaine EMDA is superior to alkalized lidocaine in that it allows for a greater distention of the bladder for a longer period of time but does not eliminate the pain of bladder distention...
  6. ncbi Sacral neuromodulation in patients with interstitial cystitis: a multicenter clinical trial
    Kristene E Whitmore
    Department of Urology, Graduate Hospital, Philadelphia, Pennsylvania, USA
    Int Urogynecol J Pelvic Floor Dysfunct 14:305-8; discussion 308-9. 2003
    ..Significant improvements were also seen in ICSI and ICPI scores. Subacute PNS appears to be effective in reducing symptom severity and increasing voided volumes in patients with IC previously unresponsive to standard therapy...
  7. ncbi Office bladder distention with electromotive drug administration (EMDA) is equivalent to distention under general anesthesia (GA)
    Amy E Rose
    Department of Urology, Stanford University Medical School, Stanford, California, USA
    BMC Urol 5:14. 2005
    ..We report the first comparative findings of patients undergoing both office distention with EMDA and distention in the operating room (OR) with GA...
  8. ncbi Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome
    Jennifer T Anger
    Department of Urology, UCLA, Box 951738, Los Angeles, CA 90095 1738, USA
    Int Urogynecol J 22:395-400. 2011
    ..In order to better understand provider treatment patterns for interstitial cystitis (IC)/painful bladder syndrome, we sought to document the therapies utilized and their associated expenditures using a national dataset...
  9. ncbi Solifenacin in overactive bladder syndrome
    Christopher K Payne
    Section of Female Urology and NeuroUrology, Stanford University School of Medicine, Stanford, California 94305-5118, USA
    Drugs 66:175-90. 2006
    ..Solifenacin is a well tolerated and efficacious agent for the treatment of OAB, significantly reducing symptoms and improving patients' quality of life...
  10. ncbi Correlation between 2 interstitial cystitis symptom instruments
    Erenee Sirinian
    Stanford University Medical Center, Stanford, California, USA
    J Urol 173:835-40. 2005
    ..We suggest using parallel wording of the pain symptom-problem pair containing the identical phrase, burning, pain, discomfort or pressure, to improve the ICSI/ICPI correlation and more accurately reflect the clinical condition...
  11. ncbi Interstitial cystitis and painful bladder syndrome
    Christopher K Payne
    Department of Urology, Stanford University, Stanford, CA, USA
    J Urol 177:2042-9. 2007
    ..We quantified the burden of interstitial cystitis/painful bladder syndrome on the health care system in the United States...
  12. ncbi A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis
    Robert Mayer
    University of Rochester, Rochester, New York, USA
    J Urol 173:1186-91. 2005
    ..CONCLUSIONS: Although the BCG safety profile was acceptable, the response rate for the primary outcome was low. Effective medical treatment for patients with moderate to severe interstitial cystitis remains elusive...
  13. ncbi Sexual function is a determinant of poor quality of life for women with treatment refractory interstitial cystitis
    J Curtis Nickel
    Department of Urology, Queen s University, Kingston General Hospital, Kingston, Ontario, Canada
    J Urol 177:1832-6. 2007
    ..Interstitial cystitis significantly negatively impacts quality of life. The demographic and clinical factors associated with decreased quality of life in these patients have not been well studied...
  14. ncbi Prospective evaluation of candidate urine and cell markers in patients with interstitial cystitis enrolled in a randomized clinical trial of Bacillus Calmette Guerin (BCG)
    Susan Keay
    Department of Medicine, University of Maryland School of Medicine, 10 N Greene Street, Baltimore, MD 21201, USA
    World J Urol 25:499-504. 2007
    ..Changes in HDF and HB-EGF levels correlated weakly with changes in urgency, but the low BCG response rate prevented identification of additional associations between biomarker changes and treatment or symptoms...
  15. ncbi Followup of patients with interstitial cystitis responsive to treatment with intravesical bacillus Calmette-Guerin or placebo
    Kathleen Joy Propert
    University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Urol 179:552-5. 2008
    ..We evaluated the longer term response in patients with interstitial cystitis who initially responded to intravesical bacillus Calmette-Guerin or placebo in a randomized clinical trial...
  16. ncbi Did patients with interstitial cystitis who failed to respond to initial treatment with bacillus Calmette-Guerin or placebo in a randomized clinical trial benefit from a second course of open label bacillus Calmette-Guerin?
    Kathleen Joy Propert
    Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Blockley Hall, 6th Floor, 423 Guardian Dr, Philadelphia, Pennsylvania 19104, USA
    J Urol 178:886-90. 2007
    ....
  17. ncbi Bladder necrosis following hydrodistention in patients with interstitial cystitis
    Nasim Zabihi
    Geffen School of Medicine at University of California Los Angeles, Los Angeles, USA
    J Urol 177:149-52; discussion 152. 2007
    ..To our knowledge this rare complication has not been previously reported in the literature. We also reviewed the literature regarding complications of hydrodistention and discuss their possible etiology...

Research Grants2

  1. Interstitial Cystitis Clinical Research Network
    Christopher Payne; Fiscal Year: 2007
    ..abstract_text> ..